{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:39Z","timestamp":1788416019149,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pancreatic ductal adenocarcinoma carries a poor prognosis, with the worst outcomes observed in UICC stage IV disease characterized by hepatic\u2014and less frequently pulmonary\u2014metastases. Considerable genetic heterogeneity, including mutations in\n                      <jats:italic>KRAS<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      , and\n                      <jats:italic>ERBB2<\/jats:italic>\n                      , enables the development of individualized therapeutic strategies. We report here a patient with\n                      <jats:italic>KRAS<\/jats:italic>\n                      - and\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      -wild-type but mutant\n                      <jats:italic>TP53<\/jats:italic>\n                      and\n                      <jats:italic>ERBB2<\/jats:italic>\n                      disease who achieved apparent remission of hepatic metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 78-year-old Caucasian male presented with newly detected dilation of the distal main pancreatic duct and prepapillary stenosis associated with a hypodiffused region. After 8 months of surveillance, rising CA19-9 levels prompted pylorus-preserving pancreaticoduodenectomy. Two small hepatic nodules were resected and confirmed as metastatic lesions. The primary tumor was identified as invasive micropapillary pancreatic ductal adenocarcinoma (PDAC). Surgery did not slow or halt the progressive rise of CA19\u20139 levels in serum. Adjuvant gemcitabine therapy was discontinued at the patient\u2019s request after four infusions, and high-dose nicotinamide treatment (3 x 500 mg per day) was initiated 11 weeks later. CA19-9 levels declined from 1376 U\/ml to the normal range within 5 months. Initial magnetic resonance imaging revealed multiple small hepatic metastases, which regressed in parallel with CA19-9 levels and were no longer detectable one and two years later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Regression of CA19-9 levels and imaging-detectable hepatic metastases occurred concurrently after initiation of high-dose nicotinamide. This temporal relationship may be incidental, and the remission could represent a delayed effect of the preceding gemcitabine infusions. Nicotinamide supplementation may also have contributed anti-tumor activity. High-dose nicotinamide elevates systemic NAD\n                      <jats:sup>+<\/jats:sup>\n                      levels, which may enhance immune function within the metastatic tumor microenvironment. In addition, partial inhibition of poly(ADP-ribose) polymerase by high-dose nicotinamide can impair DNA repair in tumor cells with underlying repair deficiencies, thereby promoting tumor cell death.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1927317","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:12Z","timestamp":1788412992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Long-term remission of metastatic pancreatic ductal adenocarcinoma after surgery and high-dose nicotinamide supplementation"],"prefix":"10.3389","volume":"16","author":[{"given":"Hubert","family":"Kolb","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]},{"name":"West-German Centre of Diabetes and Health, D\u00fcsseldorfer Kliniken der Franziskus-Stiftung","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hartwig","sequence":"additional","affiliation":[{"name":"Department of Surgery, Evangelisches Krankenhaus D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Beyna","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Evangelisches Krankenhaus D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"auf der Horst","sequence":"additional","affiliation":[{"name":"West-German Centre of Diabetes and Health, D\u00fcsseldorfer Kliniken der Franziskus-Stiftung","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Kempf","sequence":"additional","affiliation":[{"name":"West-German Centre of Diabetes and Health, D\u00fcsseldorfer Kliniken der Franziskus-Stiftung","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Martin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]},{"name":"West-German Centre of Diabetes and Health, D\u00fcsseldorfer Kliniken der Franziskus-Stiftung","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Struse-Soll","sequence":"additional","affiliation":[{"name":"Oncology Medical Care Center, Sana Clinics Gerresheim","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dommach","sequence":"additional","affiliation":[{"name":"Oncology Medical Care Center, Sana Clinics Gerresheim","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","unstructured":"ECIS, Presentations and recording - Estimating the cancer burden in the EU: Insights from the European Cancer Information System (2 February 2026) - Public Health\n          Presentations and recording - Estimating the cancer burden in the EU: Insights from the European Cancer Information System\n          \n          2026"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010057","article-title":"Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: A propensity score-matched SEER database analysis","volume":"14","author":"Pausch","year":"2021","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002338","article-title":"Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes","volume":"111","author":"Fiorillo","year":"2025","journal-title":"Int J Surg (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27734","article-title":"Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials","volume":"119","author":"Bauer","year":"2013","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i8.736","article-title":"Developments in metastatic pancreatic cancer: is gemcitabine still the standard","volume":"18","author":"Ying","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"189618","DOI":"10.1016\/j.bbcan.2026.189618","article-title":"Immune remodeling of liver metastases: From molecular mechanisms to therapeutic strategies","volume":"1881","author":"Xu","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10555-026-10334-1","article-title":"The immunobiology of pancreatic cancer metastasis: premetastatic niche formation, organ-specific immune landscapes, and therapeutic opportunities","volume":"45","author":"Principe","year":"2026","journal-title":"Cancer metastasis Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","article-title":"Looking beyond checkpoint inhibitor monotherapy: Uncovering new frontiers for pancreatic cancer immunotherapy","volume":"24","author":"Giurini","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S390655","article-title":"Second-line treatment of pancreatic adenocarcinoma: Shedding light on new opportunities and key talking points from clinical trials","volume":"17","author":"Imperial","year":"2024","journal-title":"Clin Exp Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010124","article-title":"Pancreatic cancer is feeling the heat","volume":"12","author":"Maru","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173085","article-title":"Biological functions and therapeutic potential of NAD+ metabolism in gynecological cancers","volume":"16","author":"Myong","year":"2024","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1745988","article-title":"Regulating the regulators via targeting CD38 in the tumor microenvironment","volume":"17","author":"Dutta","year":"2026","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2026.104145","article-title":"Why is the tumor microenvironment disordered by NADH\/NAD+ imbalance and how can we intervene","volume":"92","author":"Li","year":"2026","journal-title":"Redox Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1150-2","article-title":"NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling","volume":"569","author":"Chowdhry","year":"2019","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0521","article-title":"Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal binding protein as a promising novel therapy for pancreatic cancer","volume":"3","author":"Dcona","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0150","article-title":"Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors","volume":"20","author":"Chini","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15096","article-title":"Possible mechanisms of cancer prevention by nicotinamide","volume":"178","author":"Buqu\u00e9","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/biom14121512","article-title":"Role of nicotinamide in the pathogenesis of actinic keratosis: Implications for NAD+\/SIRT1 pathway","volume":"14","author":"Belardi","year":"2024","journal-title":"Biomolecules"},{"key":"B22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00403-025-04296-7","article-title":"Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients","volume":"317","author":"Hwang","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-01005-y","article-title":"Nicotinamide for skin cancer chemoprevention: The jury was out and still is","volume":"27","author":"Tan","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"B24","article-title":"Nicotinamide in type 1 diabetes. Mechanism of action revisited","author":"Kolb","year":"1999","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)83741-3","article-title":"Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo","volume":"264","author":"Rankin","year":"1989","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/6535","article-title":"Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin","volume":"5","author":"Burkart","year":"1999","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03120-6","article-title":"Novel insights into PARPs in gene expression: regulation of RNA metabolism","volume":"76","author":"Ke","year":"2019","journal-title":"Cell Mol Life Sci CMLS"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.6.980","article-title":"The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group","volume":"47","author":"Lampeter","year":"1998","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP inhibitors: molecular mechanisms and clinical applications","volume":"6","author":"Wang","year":"2025","journal-title":"Mol BioMed"},{"key":"B31","first-page":"197","article-title":"Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions","volume":"24","author":"Linville","year":"2026","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1593\/neo.12414","article-title":"Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents","volume":"14","author":"Reiner","year":"2012","journal-title":"Neoplasia (New York NY)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040653","article-title":"The prognostic impact of HER2 genetic and protein expression in pancreatic carcinoma-HER2 protein and gene in pancreatic cancer","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jso.70060","article-title":"P53 function status correlates with overall survival in patients with resected pancreatic cancer","volume":"132","author":"Chen","year":"2025","journal-title":"J Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1169586","article-title":"Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma","volume":"13","author":"Ashok Kumar","year":"2023","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251339939","article-title":"Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort","volume":"17","author":"Trystram","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/freae.2025.1723159","article-title":"Epigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications","volume":"3","author":"Sultana","year":"2025","journal-title":"Front Epigenet Epigenomics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i20.100169","article-title":"Radiofrequency ablation of liver metastases in a patient with pancreatic cancer and long-term survival: A case report","volume":"13","author":"Yong","year":"2025","journal-title":"World J Clin cases"},{"key":"B42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.70352\/scrj.cr.26-0003","article-title":"Sustained complete remission after radiofrequency ablation for liver oligometastasis from pancreatic cancer despite persistent carbohydrate antigen 19-9 elevation: A case report","volume":"12","author":"Takahashi","year":"2026","journal-title":"Surg Case Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3892\/ol.2024.14503","article-title":"Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report","volume":"28","author":"Mayuko","year":"2024","journal-title":"Oncol Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.51821\/87.4.11787","article-title":"Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation","volume":"87","author":"Crap\u00e9","year":"2024","journal-title":"Acta gastro-enterologica Belgica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:14Z","timestamp":1788412994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1927317"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1927317","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1927317"}}